[早期乳腺癌辅助 S-1 加内分泌治疗--两个病例的报告]。

Q4 Medicine Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01
Keita Adachi, Junko Nagae, Hitomi Kubota, Shuhei Suzuki, Tomohiro Hirano, Natsuki Saigusa, Takuo Henmi, Hisao Yagishita, Hitoshi Tsuda, Kenichi Sakurai
{"title":"[早期乳腺癌辅助 S-1 加内分泌治疗--两个病例的报告]。","authors":"Keita Adachi, Junko Nagae, Hitomi Kubota, Shuhei Suzuki, Tomohiro Hirano, Natsuki Saigusa, Takuo Henmi, Hisao Yagishita, Hitoshi Tsuda, Kenichi Sakurai","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We report 2 cases of early breast cancer treated with adjuvant S-1 plus endocrine therapy. In case 1, a 70-year-old woman was diagnosed with right breast cancer and underwent partial mastectomy. The histopathological diagnosis was invasive ductal carcinoma(solid type), positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 labeling index was 14%. The diameter of invasion was 27 mm, no lymph node metastasis was observed, and we confirmed the diagnosis as pT2N0M0, Stage ⅡA. A venous invasion was observed and the histological grade was Ⅱ. In case 2, a 53-year-old woman was diagnosed with left breast cancer and underwent lumpectomy. The histopathological findings showed a solid-tubular carcinoma, characterized by ER-positive, PgR-positive, HER2-negative. The Ki-67 labeling index was 24%. The tumor had an invasion of 20 mm and was diagnosed as Stage Ⅰ early-stage cancer, but there were some venous invasions and the histological grade was Ⅲ. We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1065-1067"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Early Breast Cancer Treated with Adjuvant S-1 plus Endocrine Therapy-A Report of Two Cases].\",\"authors\":\"Keita Adachi, Junko Nagae, Hitomi Kubota, Shuhei Suzuki, Tomohiro Hirano, Natsuki Saigusa, Takuo Henmi, Hisao Yagishita, Hitoshi Tsuda, Kenichi Sakurai\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We report 2 cases of early breast cancer treated with adjuvant S-1 plus endocrine therapy. In case 1, a 70-year-old woman was diagnosed with right breast cancer and underwent partial mastectomy. The histopathological diagnosis was invasive ductal carcinoma(solid type), positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 labeling index was 14%. The diameter of invasion was 27 mm, no lymph node metastasis was observed, and we confirmed the diagnosis as pT2N0M0, Stage ⅡA. A venous invasion was observed and the histological grade was Ⅱ. In case 2, a 53-year-old woman was diagnosed with left breast cancer and underwent lumpectomy. The histopathological findings showed a solid-tubular carcinoma, characterized by ER-positive, PgR-positive, HER2-negative. The Ki-67 labeling index was 24%. The tumor had an invasion of 20 mm and was diagnosed as Stage Ⅰ early-stage cancer, but there were some venous invasions and the histological grade was Ⅲ. We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.</p>\",\"PeriodicalId\":35588,\"journal\":{\"name\":\"Japanese Journal of Cancer and Chemotherapy\",\"volume\":\"51 10\",\"pages\":\"1065-1067\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Cancer and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

我们报告了 2 例早期乳腺癌患者接受 S-1 加内分泌辅助治疗的病例。在病例 1 中,一名 70 岁的妇女被诊断为右侧乳腺癌,并接受了部分乳房切除术。组织病理诊断为浸润性导管癌(实体型),雌激素受体(ER)和孕激素受体(PgR)阳性,HER2/neu阴性。Ki-67标记指数为14%。浸润直径为 27 毫米,未发现淋巴结转移,确诊为 pT2N0M0,ⅡA 期。观察到静脉侵犯,组织学分级为Ⅱ级。病例 2:一名 53 岁女性被诊断为左侧乳腺癌,并接受了肿块切除术。组织病理结果显示为实性管状癌,特征为ER阳性、PgR阳性、HER2阴性。Ki-67标记指数为24%。肿瘤侵犯范围为 20 毫米,诊断为Ⅰ期早期癌,但有部分静脉侵犯,组织学分级为Ⅲ级。我们判断这两名患者都有中度复发风险,因此在内分泌治疗的基础上加用了 S-1。即使在没有腋窝淋巴结转移的病例中,如果符合 POTENT 试验的标准,S-1 与内分泌治疗的组合也被认为是一种有效的治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Early Breast Cancer Treated with Adjuvant S-1 plus Endocrine Therapy-A Report of Two Cases].

We report 2 cases of early breast cancer treated with adjuvant S-1 plus endocrine therapy. In case 1, a 70-year-old woman was diagnosed with right breast cancer and underwent partial mastectomy. The histopathological diagnosis was invasive ductal carcinoma(solid type), positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 labeling index was 14%. The diameter of invasion was 27 mm, no lymph node metastasis was observed, and we confirmed the diagnosis as pT2N0M0, Stage ⅡA. A venous invasion was observed and the histological grade was Ⅱ. In case 2, a 53-year-old woman was diagnosed with left breast cancer and underwent lumpectomy. The histopathological findings showed a solid-tubular carcinoma, characterized by ER-positive, PgR-positive, HER2-negative. The Ki-67 labeling index was 24%. The tumor had an invasion of 20 mm and was diagnosed as Stage Ⅰ early-stage cancer, but there were some venous invasions and the histological grade was Ⅲ. We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
337
期刊最新文献
[Online Survey about Communication between Abemaciclib-Treated Patients with Breast Cancer and Physicians]. [Survey on the Size of Oral Anticancer Drugs]. [Ⅰ. Personalized Perioperative Therapy in Luminal Breast Cancer]. [Ⅱ. Recurrence Score in Patients with BRCA1/2 Mutation from the OlympiA and TAILORx Trial Results]. [Ⅲ. MONARCH-E and Oncotype DX].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1